Literature DB >> 8119321

delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats.

A P Wickens1, R G Pertwee.   

Abstract

Doses of 3 or 30 micrograms of delta 9-tetrahydrocannabinol markedly increased the ability of 25 ng of muscimol to delay the descent of rats from a horizontal bar (descent latency) when these drugs were coadministered bilaterally into the globus pallidus. Intrapallidal injections of 30 micrograms of the putative endogenous cannabinoid, anandamide, also increased the effect of muscimol on descent latency. These data indicate that the production of catalepsy by cannabinoids may depend at least in part on an ability to enhance GABAergic transmission in the globus pallidus and support the hypothesis that anandamide is indeed an endogenous ligand for the cannabinoid receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119321     DOI: 10.1016/0014-2999(93)90646-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.

Authors:  J Romero; F Berrendero; L García-Gil; J A Ramos; J J Fernández-Ruiz
Journal:  J Mol Neurosci       Date:  1998-10       Impact factor: 3.444

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Long-term synaptic transformation of hippocampal CA1 gamma-aminobutyric acid synapses and the effect of anandamide.

Authors:  C Collin; W A Devane; D Dahl; C J Lee; J Axelrod; D L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

4.  Delta(9)-THC-induced cognitive deficits in mice are reversed by the GABA(A) antagonist bicuculline.

Authors:  S A Varvel; E Anum; F Niyuhire; L E Wise; A H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2004-08-20       Impact factor: 4.530

Review 5.  The endocannabinoid system as a target for the treatment of motor dysfunction.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

Review 6.  Overview of Cannabis including Kampo Medicine and Therapy for Treatment of Dementia: A Review.

Authors:  Tibor Wenger; Kazuhito Watanabe; Yui Sasaki; Keiko Kanazawa; Koichi Shimizu; Supaart Sirikantaramas; Yoshinari Shoyama; Futoshi Taura; Satoshi Morimoto; Yukihiro Shoyama
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.